Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01847391 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study to Assess the Safety,Tolerability, and Pharmacokinetics of GS-6615 in Healthy Subjects
A Phase 1 study of Ischemic Heart Disease, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT01847391 is a Phase 1 study of Ischemic Heart Disease that has completed, run by Gilead Sciences. The registered enrollment target is 36 participants, below the 264-participant average among 14 other Ischemic Heart Disease trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01847391, a Phase 1 study of Ischemic Heart Disease, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase 1, single-blind, randomized, placebo-controlled, multiple ascending dose study aimed to assess the safety, tolerability, and pharmacokinetics of GS-6615 in healthy subjects.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG GS-6615
Study Locations (1)
Wisconsin
- Investigational Site - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2013-05 |
| Est. Completion | 2013-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01847391
The ClinicalTrials.gov registry entry for NCT01847391 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 264-participant average among 14 other Ischemic Heart Disease trials with a reported enrollment target (86% lower). The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ischemic Heart Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01847391 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT01847391 about?
NCT01847391 is a clinical study titled "A Phase 1 Study to Assess the Safety,Tolerability, and Pharmacokinetics of GS-6615 in Healthy Subjects". This is a phase 1, single-blind, randomized, placebo-controlled, multiple ascending dose study aimed to assess the safety, tolerability, and pharmacokinetics of GS-6615 in healthy subjects.
What is the current status of trial NCT01847391?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2013-05. Estimated completion is 2013-11.
What conditions does trial NCT01847391 study?
This clinical trial studies the following conditions: Ischemic Heart Disease.
What interventions are being tested in trial NCT01847391?
The interventions under investigation include: Placebo (DRUG), GS-6615 (DRUG).
Who is sponsoring clinical trial NCT01847391?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01847391 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ischemic Heart Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor
RECRUITING
-
Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)
RECRUITING
-
Pulsed Field Ablation for Post-Infarction Ventricular Tachycardia
RECRUITING · NA
-
Single or Repeated Intravenous Administration of umbiliCAl Cord Mesenchymal sTrOmal Cells in Ischemic Cardiomyopathy
RECRUITING · Phase 2
-
Use of GeriKit to Better Phenotype Older Adults With Ischemic Heart Disease
RECRUITING · NA
-
Development of CIRC Technologies
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.